Bildkälla: Stockfoto

Fluoguide Q3 2021: Eventful times - Redeye

Redeye comments on Fluoguide’s Q3 2021 report, following an eventful period for the company. From now on, we view clinical trial data as the primary catalyst that can induce a share price re-rating.

Redeye comments on Fluoguide’s Q3 2021 report, following an eventful period for the company. From now on, we view clinical trial data as the primary catalyst that can induce a share price re-rating.
Börsvärldens nyhetsbrev
ANNONSER